

## MOLECULAR CANCER THERAPEUTICS

## TABLE OF CONTENTS

## HIGHLIGHTS

## 1219 Selected Articles from This Issue

## SMALL MOLECULE THERAPEUTICS

## 1221 Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality

Ying Xu, Qianqian Wang, Kunjie Xiao, Zhihao Liu, Lifeng Zhao, Xuejiao Song, Xi Hu, Zhanzhan Feng, Tiantao Gao, Weiqiong Zuo, Jun Zeng, Ningyu Wang, and Luoting Yu

1232 Type I IFN, Ly6C<sup>+</sup> cells, and Phagocytes Support Suppression of Peritoneal Carcinomatosis Elicited by a TLR and CLR Agonist Combination

Allison M. Dyevoich and Karen M. Haas

## 1243 A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

Ozge Akbulut, Deniz Lengerli, Ozge Saatci, Elif Duman, Urartu O.S. Seker, Aynur Isik, Aytakin Akyol, Burcu Caliskan, Erden Banoglu, and Ozgur Sahin

## 1255 FGFR Inhibition Enhances Sensitivity to Radiation in Non-small Cell Lung Cancer

Gopika SenthilKumar, Michael M. Fisher, Justin H. Skiba, Margot C. Miller, Sean R. Brennan, Saakshi Kaushik, Samantha T. Bradley, Colin A. Longhurst, Darya Buehler, Kwangok P. Nickel, Gopal Iyer, Randall J. Kimple, and Andrew M. Baschnagel

1266 Cabozantinib Reverses Renal Cell Carcinoma-mediated Osteoblast Inhibition in Three-dimensional Coculture *In Vitro* and Reduces Bone Osteolysis *In Vivo*

Tianhong Pan, Mariane Martinez, Kelsea M. Hubka, Jian H. Song, Song-Chang Lin, Guoyu Yu, Yu-Chen Lee, Gary E. Gallick, Shi-Ming Tu, Daniel A. Harrington, Mary C. Farach-Carson, Sue-Hwa Lin, and Robert L. Satcher

## 1279 CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma

Ling Zeng, Anatoly Nikolaev, Chuan Xing, Deborah L. Della Manna, and Eddy S. Yang

## 1289 Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor

Alfonso García-Valverde, Jordi Rosell, Garazi Serna, Claudia Valverde, Joan Carles, Paolo Nuciforo, Jonathan A. Fletcher, Joaquín Arribas, Oliver Politz, and César Serrano

## LARGE MOLECULE THERAPEUTICS

1298 Biophysical and Immunological Characterization and *In Vivo* Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab

Beth Hutchins, Gary C. Starling, Mark A. McCoy, Danuta Herzyk, Frederique M. Poulet, John Dulos, Liming Liu, Soonmo Peter Kang, Laurence Fayadat-Dilman, Mark Hsieh, Christine L. Andrews, Gulesi Ayanoglu, Constance Cullen, Rene de Waal Malefyt, Robert A. Kastelein, Sabine Le Saux, Julie Lee, Sophie Li, Dan Malashock, Svetlana Sadekova, George Soder, Hans van Eenennaam, Aarron Willingham, Ying Yu, Michel Streuli, Gregory J. Carven, and Andrea van Elsas

## CANCER BIOLOGY AND TRANSLATIONAL STUDIES

## 1308 Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy

Sriram Anbil, Michael Pigula, Huang-Chiao Huang, Srivalleesha Mallidi, Mans Broekgaarden, Yan Baglo, Pushpamali De Silva, Diane M. Simeone, Mari Mino-Kenudson, Edward V. Maytin, Imran Rizvi, and Tayyaba Hasan

# TABLE OF CONTENTS


- 1320** **Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABC11/MRP8 Overexpression in a Clinically Paired Resistance Model**  
Tomoko Funazo, Takahiro Tsuji, Hiroaki Ozasa, Koh Furugaki, Yasushi Yoshimura, Tetsuya Oguri, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Yuichi Sakamori, Hironori Yoshida, Young Hak Kim, and Toyohiro Hirai
- 1328** **Depatuzumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR<sup>Y1068</sup> Phosphorylation**  
Caroline von Achenbach, Manuela Silginer, Vincent Blot, William A. Weiss, and Michael Weller
- 1340** **Gefitinib Inhibits Invasion and Metastasis of Osteosarcoma via Inhibition of Macrophage Receptor Interacting Serine-Threonine Kinase 2**  
Caroline Maloney, Michelle P. Kallis, Morris Edelman, Christopher Tzanavaris, Martin Lesser, Samuel Z. Soffer, Marc Symons, and Bettie M. Steinberg
- 1351** **A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma**  
Nagendra K. Chaturvedi, Matthew J. Kling, Connor N. Griggs, Varun Kesherwani, Mamta Shukla, Erin M. McIntyre, Sutapa Ray, Yutong Liu, Timothy R. McGuire, J. Graham Sharp, Hamid Band, Shantaram S. Joshi, and Don W. Coulter
- 1363** **Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma**  
**AC** Shinya Ohashi, Osamu Kikuchi, Yukie Nakai, Tomomi Ida, Tomoki Saito, Yuki Kondo, Yoshihiro Yamamoto, Yosuke Mitani, Trang H. Nguyen Vu, Keita Fukuyama, Hiroshi Tsukihara, Norihiko Suzuki, and Manabu Muto
- 1373** **An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer**  
**AC** Nancy A. Dawson, Matthew Zibelman, Timothy Lindsay, Rebecca A. Feldman, Michelle Saul, Zoran Gatalica, W. Michael Korn, and Elisabeth I. Heath

**AC** AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

In this issue, Pan and colleagues demonstrate that stimulating osteoblast differentiation (cabozantinib) prevents osteolysis in preclinical models of renal cell carcinoma (RCC) bone metastasis. Using a 3D co-culture system, they demonstrate the effects of cabozantinib and BMP4 (to promote bone formation) on overcoming BIGH3-inhibited osteoblast differentiation. In vivo studies confirmed the potential for cabozantinib in restricting bone lesions. The image shows TRAP staining cells (osteoclasts) in osteolytic bone metastasis from RCC. As shown in this image, there are fewer osteoclasts detected in mice treated with cabozantinib, indicative of a direct inhibitory effect of cabozantinib on osteoclasts. Read the full article on page 1266.



# Molecular Cancer Therapeutics

**19 (6)**

*Mol Cancer Ther* 2020;19:1219-1382.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/19/6>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/19/6>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.